GlassScriptPhysician profile
Matthew J Osenbaugh
NPI 1649587593
$8,742.70
in general payments reported to CMS, 2019-2025
28 companies · $2,207 in 2025
The $2,207 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $1,893 · 2023: $2,627 · 2024: $1,897 · 2025: $2,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,365 · Education: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,364.96 |
| Education | $365.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,780.95 | 2021-2025 | |
| Janssen Biotech, INC. | $1,639.91 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,492.78 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $917.11 | 2022-2025 | Xifaxan, Trulance, Uceris |
| Lilly USA, LLC | $444.36 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $307.43 | 2022-2024 | Dificid, Zinplava |
| Regeneron Healthcare Solutions, INC. | $219.25 | 2022-2025 | Dupixent |
| Celgene Corporation | $199.33 | 2022-2024 | Zeposia |
| Pfizer INC. | $175.32 | 2022-2025 | |
| Genzyme Corporation | $170.42 | 2022-2025 | |
| Ardelyx, INC. | $168.02 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $161.52 | 2022-2024 | Injectafer |
| Aimmune Therapeutics, INC. | $138.38 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $134.49 | 2024-2025 | Iqirvo |
| Gilead Sciences, INC. | $129.09 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $121.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $109.14 | 2022-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $104.11 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $85.26 | 2022-2023 | |
| Organon LLC | $75.77 | 2022-2024 | Renflexis, Hadlima |
| Mauna Kea Technologies, INC. | $38.40 | 2024 | |
| Celltrion USA INC. | $32.02 | 2025 | Vegzelma |
| Pharmacosmos Therapeutics INC. | $23.15 | 2024 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $16.76 | 2024 | Zeposia |
| Qol Medical, LLC | $15.25 | 2022 | |
| Biocon Biologics INC | $15.13 | 2025 | Yesintek |
| Braintree Laboratories, INC. | $14.03 | 2022 | |
| Redhill Biopharma INC. | $13.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Osenbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.